Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neopeptide-loaded dendritic cell vaccine (Radboud University Medical Center)
- Development stage
- Unknown
- Lead developer
- Radboud University Medical Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intranodal
01
Overview
This neopeptide-loaded dendritic cell vaccine is an investigational autologous cell-based immunotherapy developed by Radboud University Medical Center for cancer prevention in individuals with Lynch syndrome. The vaccine is composed of mature dendritic cells derived from the patient's own blood, which are then pulsed with HLA-A2-binding short peptides. These peptides are derived from three specific sources: carcinoembryonic antigen (CEA) and frameshift-derived neoantigens from caspase-5 and TGF-βRII. The mechanism involves the dendritic cells presenting these antigens to the immune system to stimulate the production of specific T cells. These T cells are intended to recognize and destroy precancerous or cancerous cells that express these neoantigens, which are frequently produced in Lynch syndrome due to DNA mismatch repair deficiency. The vaccine is currently being evaluated in the Phase I/II PREVENT-Lynch clinical trial.
- Other names
- DC vaccinationneopeptide-loaded dendritic cellsmulti-epitope vaccination for tumour prevention in Lynch Syndrome
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)Frameshift-derived neoantigens from mismatch repair-deficient/microsatellite instability-high tumors
Beyond the preview
Go deeper on neopeptide-loaded dendritic cell vaccine (Radboud University Medical Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neopeptide-loaded dendritic cell vaccine (Radboud University Medical Center).